翻訳と辞書 |
NGR-hTNF (antitumor recombinant protein) : ウィキペディア英語版 | NGR-hTNF (antitumor recombinant protein)
NGR-hTNF is an experimental antitumor drug designed to act on tumor blood vessels.〔(【引用サイトリンク】title= NGR hTNF among the Top 10 )〕〔(【引用サイトリンク】title= MolMed a New Patent on Its Anticancer Drug NGR-hTNF )〕 It is currently undergoing Phase III clinical trials 〔(【引用サイトリンク】title= MolMed PhaseIII Trial on NGRhTNF )〕 for treatment of malignant pleural mesothelioma caused by exposure to asbestos.〔(【引用サイトリンク】title= Multidisciplinary treatment )〕〔(【引用サイトリンク】title= MolMed starts Phase III of NGRhTNF )〕 NGR-hTNF is also being investigated, alone or in combination with chemotherapy, on four different solid tumors in four other randomized Phase II trials.〔(【引用サイトリンク】title= MolMed new data ngr htnf )〕 NGR-hTNF is a recombinant protein derived from the fusion between peptide CNGRCG 〔(【引用サイトリンク】title= Safety and anticancer activity of low dose regimen of NGR-hTNF )〕 and human tumor necrosis factor alpha (TNFα).〔(【引用サイトリンク】title= Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration )〕 Once it has reached the tumor, NGR-hTNF performs its antitumor action. The Phase III (NGR015) 〔(【引用サイトリンク】title= MolMed Completes Enrolment in Pivotal Phase III )〕 clinical trial is in progress in 35 clinical centers in Europe (Italy, UK, Ireland, Poland and Belgium), USA, Canada and Egypt. NGR-hTNF is the only drug being tested in Phase III trials 〔(【引用サイトリンク】title= MolMed starts Phase III trial of NGR-hTNF in mesothelioma )〕 for the treatment of relapsed Mesothelioma, and has been granted Orphan Drug designation both in Europe and USA. 〔(【引用サイトリンク】title= US FDA Grants Orphan Status to Mesothelioma Drug )〕〔(【引用サイトリンク】title= MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States )〕 == References ==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「NGR-hTNF (antitumor recombinant protein)」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|